{
  "ticker": "AGIO",
  "company_name": "Agios Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03548220",
      "title": "A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Pyruvate Kinase Deficiency, Anemia, Hemolytic",
      "start_date": "2018-08-09",
      "completion_date": "2020-10-09",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02492737",
      "title": "Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies",
      "start_date": "2015-08-07",
      "completion_date": "2018-03-21",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04145128",
      "title": "A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2019-10-02",
      "completion_date": "2019-12-18",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03481738",
      "title": "Pyruvate Kinase Deficiency Global Longitudinal Registry",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "",
      "condition": "Pyruvate Kinase Deficiency",
      "start_date": "2018-04-23",
      "completion_date": "2027-05-31",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03564821",
      "title": "IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "IDH1 Mutation Myeloid Neoplasms",
      "start_date": "2019-01-16",
      "completion_date": "2023-06-06",
      "enrollment": 0,
      "sponsor": "Massachusetts General Hospital"
    },
    {
      "nct_id": "NCT06286033",
      "title": "Single and Multiple Ascending Dose Study and Food Effect Study for AG181",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2024-02-20",
      "completion_date": "2025-10-09",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04056910",
      "title": "Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Advanced Solid Tumor, IDH1 Mutation, Glioma",
      "start_date": "2021-09-20",
      "completion_date": "2023-11-13",
      "enrollment": 0,
      "sponsor": "Jason J. Luke, MD"
    },
    {
      "nct_id": "NCT07241234",
      "title": "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Participants With Phenylketonuria",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE1",
      "condition": "Phenylketonuria",
      "start_date": "2026-03",
      "completion_date": "2028-01-17",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04902833",
      "title": "Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "",
      "condition": "Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Myeloid Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Clonal Cytopenia of Undetermined Significance, Other Clonal Myeloid Neoplasm, Unexplained Coombs-negative Non-immune Hemolytic Anemia",
      "start_date": "2022-02-01",
      "completion_date": "2026-12-31",
      "enrollment": 0,
      "sponsor": "Massachusetts General Hospital"
    },
    {
      "nct_id": "NCT04964323",
      "title": "Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia, Anemia, Hemolytic",
      "start_date": "2021-07-02",
      "completion_date": "2023-06-30",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 7,
      "PHASE1": 28,
      "": 6,
      "PHASE2": 6,
      "EARLY_PHASE1": 1,
      "PHASE2, PHASE3": 1,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "COMPLETED": 33,
      "ACTIVE_NOT_RECRUITING": 9,
      "NOT_YET_RECRUITING": 2,
      "TERMINATED": 3,
      "RECRUITING": 3
    },
    "active_trials": 12,
    "completed_trials": 33,
    "conditions": [
      "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies",
      "Advanced Solid Tumor, IDH1 Mutation, Glioma",
      "Advanced Solid Tumors, Lymphoma",
      "Anemia",
      "Healthy",
      "Healthy Male Participants",
      "Healthy Participants",
      "Healthy Volunteer",
      "Healthy Volunteers",
      "Healthy Volunteers, Anemia, Sickle Cell",
      "Healthy, Japanese, Non-Asian",
      "Hematologic Neoplasms",
      "Hepatic Impairment",
      "IDH1 Mutation Myeloid Neoplasms",
      "Lymphoma",
      "Moderate Hepatic Impairment",
      "Myelodysplastic Syndromes",
      "Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia",
      "Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia",
      "Phenylketonuria",
      "Pyruvate Kinase Deficiency",
      "Pyruvate Kinase Deficiency, Anemia, Hemolytic",
      "Pyruvate Kinase Deficiency, Congenital Non-Spherocytic Hemolytic Anemia",
      "Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia, Anemia, Hemolytic",
      "Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Myeloid Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Clonal Cytopenia of Undetermined Significance, Other Clonal Myeloid Neoplasm, Unexplained Coombs-negative Non-immune Hemolytic Anemia",
      "Sickle Cell Disease",
      "Sickle Cell Disease, Nephropathy",
      "Thalassemia",
      "Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:43:37.233834",
    "search_query": "Agios Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Agios+Pharmaceuticals,+Inc."
  }
}